title: Vanishing bile-duct syndrome following liver transplantation--is it reversible?
abstract: Loss of bile ducts is a characteristic feature of chronic rejection in the liver allograft (also known as irreversible rejection and vanishing bile-duct syndrome). Typically, this occurs as a progressive lesion resulting in irreversible damage and graft failure requiring retransplantation. In this study, we describe 6 patients who developed a transient loss of bile ducts following liver transplantation. This occurred in a series of 138 patients who underwent the first 160 liver transplant operations in the Birmingham Liver Transplant Programme (incidence = 4.4% of patients, 3.7% of grafts). Forty needle biopsies were obtained from the 6 patients between 6 and 1303 days after transplantation. Thirteen specimens, taken between 8 and 1253 days posttransplant (median 98 days) showed an absence of bile ducts in more than 50% of portal tracts. Other histologic features of chronic rejection, inflammatory bile-duct lesions, perivenular cholestasis, and hepatocyte dropout were also seen in these biopsies, and severe cholestasis was present biochemically (median serum bilirubin level 240 mumol/L). The histologic and biochemical changes were thought to be compatible with a diagnosis of chronic/irreversible rejection, but the decision to carry out retransplantation was deferred on the basis of stable and, subsequently, improving biochemistry. Follow-up biopsies showed recovery of duct loss and other histologic abnormalities. All 6 patients are currently alive and well with good graft function. It is concluded that a transient, reversible bile-duct loss can occur after liver transplantation and that cases with this condition are indistinguishable from those who subsequently develop irreversible graft damage. In view of the risks associated with additional immunosuppression and/or retransplantation, caution is advocated in the interpretation of ductopenia in posttransplant liver biopsies. We suggest that the term "early chronic rejection" might be appropriate to describe cases in which a definite diagnosis of irreversible graft damage cannot be made.
authors.affiliation: Department of Pathology, Medical School, University of Birmingham, United Kingdom.
authors.forename: S G
authors.initials: SG
authors.lastname: Hubscher
authors.forename: J A
authors.initials: JA
authors.lastname: Buckels
authors.forename: E
authors.initials: E
authors.lastname: Elias
authors.forename: P
authors.initials: P
authors.lastname: McMaster
authors.forename: J
authors.initials: J
authors.lastname: Neuberger
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001649:Bile Duct Diseases / Q000209:etiology* / Q000628:therapy; D001652:Bile Ducts / Q000473:pathology; D001663:Bilirubin / Q000097:blood; D003586:Cytomegalovirus Infections / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male
chemical_list: D006680:HLA Antigens; D001663:Bilirubin